Syndax Pharmaceuticals, Inc. Increase (Decrease) in Accounts Receivable and Other Operating Assets
Syndax Pharmaceuticals, Inc. (SNDX) reported Increase (Decrease) in Accounts Receivable and Other Operating Assets of -$3.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2026-06-30 was $2.44M, a 6146.15% increase year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2026-03-31 was -$6.14M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2025-12-31 was $6.40M, a 4903.13% increase year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable and other operating assets for the quarter ending 2025-09-30 was $38.00K.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable and other operating assets for fiscal 2025 was $6.44M, a 77.06% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable and other operating assets for fiscal 2024 was $3.63M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable and other operating assets for fiscal 2023 was $0.00.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts receivable and other operating assets for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable and Other Operating Assets 3 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 6 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 9 month | Increase (Decrease) in Accounts Receivable and Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$3.70M 10-Q · filed 2026-08-04 | $2.70M derived: sum of 3 quarters · filed 2026-08-04 | $2.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$6.14M 10-Q · filed 2026-04-30 | $267.00K derived: sum of 2 quarters · filed 2026-04-30 | $305.00K derived: sum of 3 quarters · filed 2026-04-30 | $344.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.44M derived: sum of 2 quarters · filed 2026-02-26 | $6.48M derived: sum of 3 quarters · filed 2026-08-04 | $6.44M 10-K · filed 2026-02-26 |
| 2025-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $77.00K derived: sum of 2 quarters · filed 2026-08-04 | $32.00K 10-Q · filed 2025-11-03 | $160.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$6.00K 10-Q · filed 2026-08-04 | $122.00K derived: sum of 3 quarters · filed 2026-08-04 | -$5.95M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$45.00K 10-Q · filed 2026-04-30 | $83.00K derived: sum of 2 quarters · filed 2026-04-30 | -$5.99M derived: sum of 3 quarters · filed 2026-04-30 | -$2.48M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.95M derived: sum of 2 quarters · filed 2026-02-26 | -$2.44M derived: sum of 3 quarters · filed 2026-02-26 | $3.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$6.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$2.57M derived: sum of 2 quarters · filed 2025-11-03 | $3.51M 10-Q · filed 2025-11-03 | $3.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $9.58M 10-Q · filed 2025-08-04 | $9.58M derived: sum of 3 quarters · filed 2026-02-26 | $9.58M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $6.07M 10-Q · filed 2025-05-05 | $6.07M derived: sum of 2 quarters · filed 2026-02-26 | $6.07M derived: sum of 3 quarters · filed 2026-02-26 | $6.07M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |